Natural history of initially mild chronic hepatitis C

被引:37
作者
Alberti, A
Benvegnù, L
Boccato, S
Ferrari, A
Sebastiani, G
机构
[1] Univ Padua, Dept Clin & Expt Med, I-35128 Padua, Italy
[2] Venetian Inst Mol Med, Padua, Italy
关键词
hepatitis C; HCV; natural history;
D O I
10.1016/j.dld.2004.06.011
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The hepatitis C virus is a leading cause of chronic liver disease, cirrhosis and hepatocellular carcinoma in western countries. Chronic hepatitis C is highly heterogeneous and many patients present with a mild form of liver disease. Population-based studies have indeed demonstrated that around 50% of hepatitis C virus carriers have persistently normal ALT and two-third have mild histological liver lesions. Studies on the natural history of initially mild chronic disease indicate that the short-term outcome is always benign. However, progression of liver fibrosis can be observed at long-term (>5-7 years) follow-up, particularly in those cases who have elevated and/or fluctuating transaminase levels. Observational prospective studies and outcome modelling projections indicate that the risk of liver disease progression towards severe fibrosis/cirrhosis is minimal at 10-15 years in hepatitis C virus carriers with persistently normal ALT, around 5-10% in patients with elevated ALT and F0 (no fibrosis) in the initial biopsy but >30-40% in chronic carriers with elevated ALT and F1 (portal fibrosis) in the initial biopsy. Cofactors like age at infection, alcohol, coinfections and liver steatosis accelerate disease progression. On the basis of these findings, patients with initially mild chronic hepatitis C and elevated ALT should be proposed for antiviral therapy in the absence of contraindications. (C) 2004 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:646 / 654
页数:9
相关论文
共 72 条
[1]   Natural history of hepatitis C [J].
Alberti, A ;
Chemello, L ;
Benvegnù, L .
JOURNAL OF HEPATOLOGY, 1999, 31 :17-24
[2]   Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection [J].
Alberti, A ;
Noventa, F ;
Benvegnù, L ;
Boccato, S ;
Gatta, A .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (12) :961-964
[3]   HEPATITIS-C VIREMIA AND LIVER-DISEASE IN SYMPTOM-FREE INDIVIDUALS WITH ANTI-HCV [J].
ALBERTI, A ;
MORSICA, G ;
CHEMELLO, L ;
CAVALLETTO, D ;
NOVENTA, F ;
PONTISSO, P ;
RUOL, A .
LANCET, 1992, 340 (8821) :697-698
[4]  
ALBERTI A, UNPUB HIST PROGRESSI
[6]   The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States [J].
Armstrong, GL ;
Alter, MJ ;
McQuillan, GM ;
Margolis, HS .
HEPATOLOGY, 2000, 31 (03) :777-782
[7]   An algorithm for the grading of activity in chronic hepatitis C [J].
Bedossa, P ;
Poynard, T .
HEPATOLOGY, 1996, 24 (02) :289-293
[8]   Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C [J].
Bennett, WG ;
Inoue, Y ;
Beck, JR ;
Wong, JB ;
Pauker, SG ;
Davis, GL .
ANNALS OF INTERNAL MEDICINE, 1997, 127 (10) :855-+
[9]   NORMAL AMINOTRANSFERASE CONCENTRATIONS IN PATIENTS WITH ANTIBODIES TO HEPATITIS-C VIRUS [J].
BRUNO, S ;
ROSSI, S ;
PETRONI, ML ;
VILLA, E ;
ZUIN, M ;
PODDA, M .
BRITISH MEDICAL JOURNAL, 1994, 308 (6930) :697-697
[10]   Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection [J].
ConryCantilena, C ;
VanRaden, M ;
Gibble, J ;
Melpolder, J ;
Shakil, AO ;
Viladomiu, L ;
Cheung, L ;
DiBisceglie, A ;
Hoofnagle, J ;
Shih, JW ;
Kaslow, R ;
Ness, P ;
Alter, HJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) :1691-1696